Photo from wikipedia
I read with interest the editorial by Crooks and Faruqi [1]. I agree with almost all of the concepts; however, given my experience, I must question why the scientific community… Click to show full abstract
I read with interest the editorial by Crooks and Faruqi [1]. I agree with almost all of the concepts; however, given my experience, I must question why the scientific community does not take a drastic decision regarding short-acting β2-agonists (SABA) use in asthma. In 2019, Martin and Harrison [2] wrote a similar editorial. SABA overreliance was identified many times as the key issue [3–5]. But nothing happens. SABA's status quo has not been overcome for more than 30 years. Why not directly eradicate SABA from asthma management? The time to leave behind SABA in asthma management is now. We wasted enough time identifying the key issue in asthma morbidity and mortality. Please, eradicate SABA. https://bit.ly/3DU4mmo
Journal Title: ERJ Open Research
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!